Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial
Titel:
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial
Auteur:
Moreau, Philippe Hulin, Cyrille Perrot, Aurore Arnulf, Bertrand Belhadj, Karim Benboubker, Lotfi Béné, Marie C Zweegman, Sonja Caillon, Hélène Caillot, Denis Corre, Jill Delforge, Michel Dejoie, Thomas Doyen, Chantal Facon, Thierry Sonntag, Cécile Fontan, Jean Mohty, Mohamad Jie, Kon-Siong Karlin, Lionel Kuhnowski, Frédérique Lambert, Jérôme Leleu, Xavier Macro, Margaret Orsini-Piocelle, Frédérique Roussel, Murielle Stoppa, Anne-Marie van de Donk, Niels W C J Wuillème, Soraya Broijl, Annemiek Touzeau, Cyrille Tiab, Mourad Marolleau, Jean-Pierre Meuleman, Nathalie Vekemans, Marie-Christiane Westerman, Matthijs Klein, Saskia K Levin, Mark-David Offner, Fritz Escoffre-Barbe, Martine Eveillard, Jean-Richard Garidi, Réda Ahmadi, Tahamtan Krevvata, Maria Zhang, Ke de Boer, Carla Vara, Sanjay Kampfenkel, Tobias Vanquickelberghe, Veronique Vermeulen, Jessica Avet-Loiseau, Hervé Sonneveld, Pieter